Company intelligence / Profile preview

SapiensBio

Ownership: Private
Development stage: Preclinical

Overview

SapiensBio has developed an integrated AI/wet-lab drug discovery platform called Sapientia. Their lead program, SBC101, is in pre-clinical development targeting severe diseases with unmet medical need. The company leverages single-cell RNA sequencing and organoid models to accelerate target validation and candidate selection.

Therapeutic areas: OtherNeurology
Modalities: Small moleculeBiologic
Industry: Biotech

Drug pipeline

6 assets

SBC113

Preclinical

5 more assets in the full pipeline.

Request access →

Partnerships

Joint R&D agreement with ADDI in the UKSelected operating company for Korea's Third National New Drug Development Project

Beyond the preview

Go deeper on SapiensBio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SapiensBio.

Explore the full profile